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Protein–protein interactionAbstract Coeliac disease is a chronic intestinal inﬂammatory condition, which is caused by an
inappropriate immune response to components of wheat family cereals in a genetically susceptible
host. Gliadins are the major pathogenic constituent of wheat; their toxicity and immunogenicity
depend on their amino acid sequence. They are known to initiate the innate and the adaptive
immune response. Nevertheless, it is not yet known how they are recognised by the intestinal
epithelium and immune cells. Toll-like receptors (TLRs) are the best-studied group of pattern
recognition receptors, which play a critical role in the initiation of innate immunity through the rec-
ognition of pathogen- and damage-associated molecular patterns. Exogenous food-derived proteins
are not yet recognised as TLR ligands. Gliadin can activate TLR signalling pathway in vitro. The
existing evidence is suggestive of the direct contribution of gliadin and/or other wheat components
to activating TLR signalling. However, the data available so far are controversial and are mainly
focussed on TLR 2 and TLR4. It is hypothesised that gliadin is a direct ligand for one of the TLRs.
If indeed gliadin is proven to be a direct ligand of TLRs, our understanding of the pathogenesis of
gastrointestinal diseases, such as colorectal cancer, will also be greatly inﬂuenced. In order to fully
appreciate the role of gliadin as a direct TLR ligand, it should be proven to interact physically with
and bind to one or more of the TLR molecules. Furthermore, it should be documented that TLR
pathway activation is the downstream effect of gliadin/TLR binding.
ª 2013 Tehran University of Medical Sciences. Published by Elsevier Ltd.D license.Introduction
Coeliac disease (CD) is a chronic intestinal inﬂammatory condi-
tion which is caused by an inappropriate immune response toproline and glutamine-rich proteins of wheat family cereals in
a genetically susceptible host. It predominantly affects the
proximal segment of the small intestine and results in disruption
of the regular epithelial dynamic. The main histological
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reduced villous-to-crypt length ratio [1]. Gluten has been identi-
ﬁed as the main toxic component of wheat family cereals and, as
such, has been compared to pathogens in terms of eliciting an
immune reaction [2]. Gliadins are a diverse group of proteins
whose toxicity and immunogenicity are highly dependent on
their amino acid sequence. Their contribution to the immune re-
sponse has been studied extensively. However, their recognition
by the intestinal epithelium has not yet been addressed [3].
Toll-like receptors
Toll-like receptors (TLRs) are the best-studied group of pattern
recognition receptors (PRRs). TLRs play a critical role in the ini-
tiation of innate immunity through the recognition of pathogen-
and damage-associated molecular patterns (PAMPs and
DAMPs, respectively). To date, 10 human and 13 mouse TLRs
have been identiﬁed. TLR1, TLR2, TLR4, TLR5 and TLR6 re-
side on the plasma membrane whereas TLR3, TLR7, TLR8 and
TLR9 are localised to the endolysosomal compartment. Engage-
ment of TLRs by their ligands results in homo- or heterodimer-
isation of TLRs; as a consequence, adaptor proteins, including
myeloid differentiation primary response protein 88 (MyD88)
and TIRAP inducing interferon b (TRIF), are recruited. All
TLRs, except TLR3, signal via the MyD88-dependent pathway
ultimately leading to activation and nuclear translocation of
the transcription factors nuclear factor (NF)-jB, activating pro-
tein-1 (AP-1), or both. TLR3 function is exclusivelymediated via
a TRIF-dependent pathway. TLR4 can signal via both MyD88-
and TRIF-dependent mechanisms. TRIF-dependent TLR sig-
nalling results in activation of interferon-regulatory factor 3
(IRF3) and NF-jB in a MyD88-independent manner. TLR
pathway activity culminates in the expression of pro-inﬂamma-
tory cytokines, type I interferon (IFN) and chemokines [4].
Thus far, the TLR ligands are classiﬁed as PAMPS, con-
served structural motifs of bacteria, fungi and viruses; or
DAMPs, endogenous proteins which are released upon tissue
injury. However, other classes of molecules are being identiﬁed
which can activate the TLR signalling pathway including but
not limited to morphine [5,6], glucuronic acid and the ethanol
metabolite ethyl-glucuronide [7], green tea polyphenol epigal-
locatechin-3-gallate [8], phenethyl isothiocyanate [9] and
parthenolide [10]. It is highly plausible that the whole reper-
toire of TLR ligands has not been discovered yet.
TLR signalling in CD
The contribution of TLR signalling to CD is deﬁnitely far
from being understood. Endogenous damage-associated pro-
teins are known to initiate an immune response via activating
TLR signalling. Hence, it is not surprising to postulate a sim-
ilar mechanism of action for gluten in the pathogenesis of CD.
In fact, in an analogy to intestinal microbiota, normal intesti-
nal epithelium is hypo-responsive to food ingredients including
gliadins, the best-studied constituents of gluten. However, the
intestinal tolerance to gliadin is lost in CD [11]. In the ﬁrst-gen-
eration genome-wide association study (GWAS) of CD, PRRs
are not identiﬁed to be signiﬁcantly associated with the disease
[12–14]. However, in the second-generation GWAS in 4533
cases and 10,750 controls, TLR7 and TLR8 loci were found
to have a suggestive (less than signiﬁcant yet important)association to the disease; both loci showed a positive correla-
tion with the gene expression levels [15]. TLR7 and TLR8 are
among the nucleotide-sensing TLRs which detect single-
stranded RNA. It has been shown that coeliac patients’ sera
contain antibodies against a peptide which was highly similar
to a viral component [16]. Furthermore, it has been previously
suggested that gliadin has sequence homology to a gastrointes-
tinal adenovirus [17,18]. However, the contribution of TLR7
and TLR8 to the pathogenesis of CD is not yet understood.
If indeed TLR signalling contributes to the pathogenesis of
CD, it has been hypothesised that the gene expression pattern
as well as genetic variants might give a clue as to the underlying
mechanism. TLR 3, 4 and 7 gene expressions were assessed in
duodenal biopsies in adult andpaediatricCD.The expression lev-
els were not different between affected children and adults. How-
ever, TLR4 gene expression was found to be signiﬁcantly
increased in CD patients (both adult and children) compared to
controls. In the immunohistochemistry analysis of TLRs,
TLR3, 4 and 7were present in 37.8%, 85.5%and 9.52%of cases,
respectively. TLR4 staining was positive in both epithelial and
mononuclear cells. There was no signiﬁcant association between
TLR4 expression and clinical features of the disease [19]. In an-
other report, TLR3, 4 and 5 gene expressions were not different
in small intestinal biopsy of controls, untreated coeliac and trea-
ted coeliac patients.However, TLR9was found to be increased in
coeliac patients compared to controls, whereas TLR2 was de-
creased in coeliac patients compared to controls [20]. In the next
study, TLR2, TLR3andTLR4gene expression andprotein levels
were measured in duodenal biopsies of coeliac children (treated
and untreated) and healthy controls. In contrast to the previous
report, TLR2, TLR3 and TLR4 gene expression and protein lev-
els were increased in coeliac patients compared to controls. The
TLR2 level was alsodifferent in untreated patients versus patients
on a gluten-free diet (GFD) [21]. TLR 2 and TLR4 gene expres-
sions were also increased in dendritic cells (DCs) and monocytes
inCD inchildren [22].A few reports also exist ongenetic variation
of TLRs inCD. TLR2 andTLR4 copy number variationwas as-
sessed in CD patients; no copy number variation was detected
[23]. No signiﬁcant association between TLR4 Ala896Gly, As-
p299Gly and Thr399Ile single-nucleotide polymorphisms (SNPs)
was detected in CD patients versus controls [24,25].
The hypotheses/ideas
TLRs along with other members of PRRs are responsible for
maintaining a hypo-responsive state to the luminal content in
the gastrointestinal tract. Intestinal luminal content is com-
posed of the resident bacteria and the food ingredients and
metabolites. Exogenous food-derived proteins are not yet
recognised as TLR ligands. Given the potential role of TLR sig-
nalling and innate immunity in the pathogenesis of CD, it is
hypothesised that gliadin is a direct ligand for one of the TLRs.
If indeed gliadin is proven to be a direct ligand of TLRs, our
understanding of the pathogenesis of gastrointestinal diseases,
such as colorectal cancer (CRC), will also be greatly inﬂuenced.
Evaluation of the hypotheses/ideas
There are only a few published functional analyses of TLR signal-
ling in CD. Catalogued TLR ligands are either PAMPs or
DAMPs.However, it has been shown that pathogenicwheat com-
46 S. Moossaviponents can also activate the TLRpathway. However, it is not yet
knownwhether they are direct ligandsof theTLRs.Pepsin/trypsin
(PT)-treated gliadin is able to up-regulate lipopolysaccharide
(LPS)-induced pro-inﬂammatory cytokines in a MyD88-depen-
dent manner. It also couldmodulate TLR2 and 4 gene expression
in macrophages. However, the inﬂammatory effect of PT-gliadin
was found not to be mediated by TLR2 or TLR4 [26]. PT-gliadin
was found to strongly activate the innate immune response in
monocyte in vitro whilst its effect on intestinal epithelial cells was
onlyminimal. In contrast to the previous report,DCs fromcoeliac
patients with active and inactive disease and healthy controls re-
sponded to gliadin via TLR4 in both MyD88-dependent and
-independent manners. This action was found to be induced by
the a-amylase/trypsin inhibitor (ATI) protein family in wheat
and related cereals [27]. The pro-inﬂammatory effect of the peptic
digest of wheat gliadin fraction (PDWGF) on peripheral blood
mononuclear cells is alsomediated viaMyD88- and TRIF-depen-
dent TLR signalling mediated by TLR2 and TLR4 [28]. In the
screening of a randompeptide librarywith sera fromactive coeliac
patients and those onGFD, one peptide was identiﬁed which was
selectively detected by serum immunoglobulin A (IgA) of active
patients and a minority of patients in remission but not in other
auto-immune disorders and not in inﬂammatory bowel disease
(IBD).The identiﬁedpeptide shared sequencehomology toanum-
berofhumanpathogenproteins including rotavirus serotype Ima-
jor neutralising protein, VP-7. Themajority of patientswith active
CD had detectable antibodies against rotavirus and an antibody
against the identiﬁed peptide. The identiﬁed peptide also had a
high degree of similarity with human proteins, including TLR4.
It was further demonstrated that antibodies against the identiﬁed
peptide and rotavirus VP-7 could activate TLR4 signalling [16].
The existing evidence is suggestive of the direct contribution
of gliadin and/or otherwheat components to activatingTLRsig-
nalling.However, the data so far are controversial andmainly fo-
cussed on TLR2 and TLR4. In order to fully appreciate the role
of gliadin as a direct TLR ligand, it should be proven to physi-
cally interactwith andbind to oneormore of theTLRmolecules.
Furthermore, it should be documented that TLR pathway
activation is the downstream effect of gliadin/TLR binding.
The hypothesis could be tested with the following
experiments:
 In silico prediction of gliadin and TLRs’ protein–pro-
tein interaction.
 In vitro protein–protein interaction investigation by
co-immunoprecipitation and pull-down assays when
the interaction is strong and stable and by crosslinking
protein interaction analysis and label transfer protein
interaction analysis when the interaction is weak and
transient.
 In vivo protein–protein interaction investigation by
protein complementation assays.
 Functional analysis of the effect of gliadin on TLR
pathway activity employing commercially available
NF-jB reporter cell lines.
 In vitro validation of the role of the identiﬁed TLR by
using TLR inhibitors or small interfering RNA
(siRNA).
 Examination of the effect of gliadin on intestinal epi-
thelium and myeloid-derived cells in knockout mice
with speciﬁc lack of the identiﬁed TLR. Investigation of a TLR agonist/antagonist in alleviat-
ing coeliac symptoms in murine models.
 Clinical trials of TLR-targeting drugs in CD.Conclusion and perspective
If indeed gliadin exerts its pathogenic contribution toCD via acti-
vating TLR signalling, it is conceivable that targeted inhibition of
the pathway or the speciﬁc responsibleTLRcould be a novel, bio-
logic, therapeutic approach to the disease. Alternatively, gliadin
could be engineered in a way which does not interact with TLRs.
Geneticallymodiﬁedwheat andother causative cereals could then
be engineered and mass-produced for coeliac patients.
If gliadin is proven to be a TLR ligand, the question on the
role of TLR signalling in the pathogenesis of major intestinal
pathologies, that is, IBD and CRC, will be signiﬁcantly af-
fected. So far, the scientiﬁc community is interested in the con-
tribution of microbiota to the pathogenesis of IBD and CRC.
Although nutrigenomics has gained interest in recent years, it
has never been fully appreciated to have an equally signiﬁcant
role in the pathogenesis of IBD and CRC. In fact, the nutrient
and metabolite components of the intestinal lumen are not yet
comprehensively catalogued.Overview Box
First Question: What do we already know about the
subject?
Innate immunity plays a crucial role in initiation of the
immune response to the pathogenic component of
wheat and wheat-family cereals in CD. TLR7 and 8
have been suggested to be associated with CD in
large-scale second-generation GWAS. Furthermore,
gliadin and ATI of wheat have been shown to activate
the TLR pathway in vitro.
Second Question: What does your proposed theory add
to the current knowledge available, and what beneﬁts
does it have?
Currently, TLR ligands are limited to micro-organisms
or endogenous conserved structural motifs. However,
if indeed gliadin, as a food component, is a TLR
ligand, TLR research will be greatly impacted. More-
over, the contribution of the luminal content to the
gastrointestinal hypo-tolerant state and aberrant
immune response following any dysregulation of the
balance will be an interesting research avenue. The
approach to identifying CRC-speciﬁc microbiota sig-
nature will be expanded to also include other luminal
content. Novel diagnostic and therapeutic strategies
could be speciﬁcally designed for CD.
Third question: Among numerous available studies, what
special further study is proposed for testing the idea?
The ﬁrst step is to assess the physical protein–protein
interaction in vitro. If such interaction is indeed identi-
ﬁed and validated, it should be further proven that it
results in TLR pathway activity.
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